Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856560 | 0.85 | SMN1; SMN2 (0.46) | KMT2ASMN1; SMN2 | |
| SCHEMBL5049340 | 0.85 | POLB (0.45) | MEN1KMT2ALPAR1SMN1; SMN2TP53 | |
| SCHEMBL855085 | 0.81 | SMN1; SMN2 (0.45) | MEN1KMT2ALPAR1SMN1; SMN2 | |
| SCHEMBL855945 | 0.81 | SOAT2 (0.47) | KMT2ASMN1; SMN2 | |
| SCHEMBL854382 | 0.81 | SOAT1 (0.47) | KMT2ASMN1; SMN2 | |
| SCHEMBL4592839 | 0.81 | OXTR (0.44) | OXTRMEN1KMT2ATAS2R14SMN1; SMN2 | |
| SCHEMBL856269 | 0.80 | GAA (0.47) | MEN1KMT2ALPAR1SMN1; SMN2 | |
| SCHEMBL856005 | 0.80 | SMN1; SMN2 (0.41) | MEN1KMT2ALPAR1SMN1; SMN2 | |
| SCHEMBL854986 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2 | |
| SCHEMBL4592247 | 0.80 | OXTR (0.42) | OXTRMEN1KMT2ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308438-B9 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-1308438-B1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7105567-B2 | 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1308438-A1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | OXTR 2182/4885MEN1 2053/4885KMT2A 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.